inclusion criteria: 1. subjects age \> 18 years at the time of signing the informed consent form. 2. male or female. 3. covid-19 survivor and had documented sars-cov-2 positive (fda eua approved rt-pcr or equivalent tests such as fda eua approved rapid antigen test which is performed at clia certified lab or the readout of the test reviewed and documented by a doctor). 4. subject experiencing fatigue for over 6 weeks after their positive test result while currently being negative. 5. subject has not fully recovered from covid-19 for at least over 6 weeks despite a negative sars-cov-02 test. 6. subjects tested positive for anti-sars-cov-2 antibodies using fda eua approved test. 7. subject is experiencing the following three symptoms for at least over 6 weeks either continually or intermittently with relapses not experienced pre-illness, that interferes with normal daily activities. symptoms must be new symptoms i.e., subject didn't have symptoms, and had not sought medical treatment for the symptoms prior to covid-19: * extreme fatigue - feeling overtired with low energy and a strong desire to sleep but unable to have good sleep. * body aches - muscle soreness or generalized achiness throughout the body. * joint pain - pain in the joints due to inflammation not experienced before illness. 8. chalder fatigue scale bimodal score ≥ 4 at the time of screening. 9. fatigue severity scale (fss) ≥ 4 at the time of screening. 10. fatigue assessment scale score (fas) ≥ 10.5 at the time of screening. 11. beck depression inventory (bdi) score \<15 at the time of screening (score of 15 is an exclusion). 12. investigator(s) has access to medical documentation of previous covid-19 treatments. 13. ability of subject to understand and the willingness to sign a written informed consent document. 14. subjects must be reasonably able to return for multiple follow-up visits. 15. adequate venous access. 16. for subjects of child-bearing potential only, willingness to use fda recommended birth control until 6 months post-treatment. the fda approved and cleared methods for birth control are listed below: * permanent sterilization * long-acting reversible contraceptives (larc) * contraceptive injection * short-acting hormonal methods * barrier methods * emergency contraception https://www.fda.gov/consumers/free-publications-women/birthcontrol 17. any male subject must agree to use contraceptives and not donate sperm during the study.

inclusion criteria: 1. subjects age \> 18 years at the time of signing the informed consent form. 2. male or female. 3. covid-19 survivor and had documented sars-cov-2 positive (fda eua approved rt-pcr or equivalent tests such as fda eua approved rapid antigen test which is performed at clia certified lab or the readout of the test reviewed and documented by a doctor). 4. subject experiencing fatigue for over 6 weeks after their positive test result while currently being negative. 5. subject has not fully recovered from covid-19 for at least over 6 weeks despite a negative sars-cov-02 test. 6. subjects tested positive for anti-sars-cov-2 antibodies using fda eua approved test. 7. subject is experiencing the following three symptoms for at least over 6 weeks either continually or intermittently with relapses not experienced pre-illness, that interferes with normal daily activities. symptoms must be new symptoms i.e., subject didn't have symptoms, and had not sought medical treatment for the symptoms prior to covid-19: * extreme fatigue - feeling overtired with low energy and a strong desire to sleep but unable to have good sleep. * body aches - muscle soreness or generalized achiness throughout the body. * joint pain - pain in the joints due to inflammation not experienced before illness. 8. chalder fatigue scale bimodal score ≥ 4 at the time of screening. 9. fatigue severity scale (fss) ≥ 4 at the time of screening. 10. fatigue assessment scale score (fas) ≥ 10.5 at the time of screening. 11. beck depression inventory (bdi) score \<15 at the time of screening (score of 15 is an exclusion). 12. investigator(s) has access to medical documentation of previous covid-19 treatments. 13. ability of subject to understand and the willingness to sign a written informed consent document. 14. subjects must be reasonably able to return for multiple follow-up visits. 15. adequate venous access. 16. for subjects of child-bearing potential only, willingness to use fda recommended birth control until 6 months post-treatment. the fda approved and cleared methods for birth control are listed below: * permanent sterilization * long-acting reversible contraceptives (larc) * contraceptive injection * short-acting hormonal methods * barrier methods * emergency contraception https://www.fda.gov/consumers/free-publications-women/birthcontrol 17. any male subject must agree to use contraceptives and not donate sperm during the study.

inclusion criteria: subjects age > 18 years at the time of signing the informed consent form. male or female. covid-19 survivor and had documented sars-cov-2 positive (fda eua approved rt-pcr or equivalent tests such as fda eua approved rapid antigen test which is performed at clia certified lab or the readout of the test reviewed and documented by a doctor). subject experiencing fatigue for over 6 weeks after their positive test result while currently being negative. subject has not fully recovered from covid-19 for at least over 6 weeks despite a negative sars-cov-02 test. subjects tested positive for anti-sars-cov-2 antibodies using fda eua approved test. subject is experiencing the following three symptoms for at least over 6 weeks either continually or intermittently with relapses not experienced pre-illness, that interferes with normal daily activities. symptoms must be new symptoms i.e., subject didn't have symptoms, and had not sought medical treatment for the symptoms prior to covid-19: extreme fatigue - feeling overtired with low energy and a strong desire to sleep but unable to have good sleep. body aches - muscle soreness or generalized achiness throughout the body. joint pain - pain in the joints due to inflammation not experienced before illness. chalder fatigue scale bimodal score ≥ 4 at the time of screening. fatigue severity scale (fss) ≥ 4 at the time of screening. fatigue assessment scale score (fas) ≥ 10.5 at the time of screening. beck depression inventory (bdi) score <15 at the time of screening (score of 15 is an exclusion). investigator(s) has access to medical documentation of previous covid-19 treatments. ability of subject to understand and the willingness to sign a written informed consent document. subjects must be reasonably able to return for multiple follow-up visits. adequate venous access. for subjects of child-bearing potential only, willingness to use fda recommended birth control until 6 months post-treatment. the fda approved and cleared methods for birth control are listed below: permanent sterilization long-acting reversible contraceptives (larc) contraceptive injection short-acting hormonal methods barrier methods emergency contraception https://www.fda.gov/consumers/free-publications-women/birthcontrol any male subject must agree to use contraceptives and not donate sperm during the study.

inclusion criteria: subjects age > 18 years at the time of signing the informed consent form. male or female. covid-19 survivor and had documented sars-cov-2 positive (fda eua approved rt-pcr or equivalent tests such as fda eua approved rapid antigen test which is performed at clia certified lab or the readout of the test reviewed and documented by a doctor). subject experiencing fatigue for over 6 weeks after their positive test result while currently being negative. subject has not fully recovered from covid-19 for at least over 6 weeks despite a negative sars-cov-02 test. subjects tested positive for anti-sars-cov-2 antibodies using fda eua approved test. subject is experiencing the following three symptoms for at least over 6 weeks either continually or intermittently with relapses not experienced pre-illness, that interferes with normal daily activities. symptoms must be new symptoms i.e., subject didn't have symptoms, and had not sought medical treatment for the symptoms prior to covid-19: extreme fatigue - feeling overtired with low energy and a strong desire to sleep but unable to have good sleep. body aches - muscle soreness or generalized achiness throughout the body. joint pain - pain in the joints due to inflammation not experienced before illness. chalder fatigue scale bimodal score ≥ 4 at the time of screening. fatigue severity scale (fss) ≥ 4 at the time of screening. fatigue assessment scale score (fas) ≥ 10.5 at the time of screening. beck depression inventory (bdi) score <15 at the time of screening (score of 15 is an exclusion). investigator(s) has access to medical documentation of previous covid-19 treatments. ability of subject to understand and the willingness to sign a written informed consent document. subjects must be reasonably able to return for multiple follow-up visits. adequate venous access. for subjects of child-bearing potential only, willingness to use fda recommended birth control until 6 months post-treatment. the fda approved and cleared methods for birth control are listed below: permanent sterilization long-acting reversible contraceptives (larc) contraceptive injection short-acting hormonal methods barrier methods emergency contraception https://www.fda.gov/consumers/free-publications-women/birthcontrol any male subject must agree to use contraceptives and not donate sperm during the study.

inclusion criteria: subjects age > 18 years at the time of signing the informed consent form. male or female. covid-19 survivor and had documented sars-cov-2 positive (fda eua approved rt-pcr). subjects with history of covid-19 infection who are experiencing prolonged fatigue over 6 weeks after their covid-19 rt-pcr negative test. subject has not fully recovered from covid-19 for at least over 6 weeks despite a negative sars-cov-02 test. subjects tested positive for anti-sars-cov-2 antibodies using fda eua approved test. subject is experiencing the following three symptoms for at least over 6 weeks either continually or intermittently with relapses not experienced pre-illness, that interferes with normal daily activities. symptoms must be new symptoms i.e., subject didn't have symptoms, and had not sought medical treatment for the symptoms prior to covid-19: extreme fatigue - feeling overtired with low energy and a strong desire to sleep but unable to have good sleep. body aches - muscle soreness or generalized achiness throughout the body. joint pain - pain in the joints due to inflammation not experienced before illness. chalder fatigue scale bimodal score ≥ 4 at the time of screening. fatigue severity scale (fss) ≥ 4 at the time of screening. fatigue assessment scale score (fas) ≥ 10.5 at the time of screening. beck depression inventory (bdi) score <9 at the time of screening (score of 9 is an exclusion). investigator(s) has access to medical documentation of previous covid-19 treatments. ability of subject to understand and the willingness to sign a written informed consent document. subjects must be reasonably able to return for multiple follow-up visits. adequate venous access. for subjects of child-bearing potential only, willingness to use fda-recommended birth control until 6 months post-treatment. the fda-approved and cleared methods for birth control are listed below: permanent sterilization long-acting reversible contraceptives (larc) contraceptive injection short-acting hormonal methods barrier methods emergency contraception any male subject must agree to use contraceptives and not donate sperm during the study.

inclusion criteria: subjects age > 18 years at the time of signing the informed consent form. male or female. covid-19 survivor and had documented sars-cov-2 positive (fda eua approved rt-pcr). subjects with history of covid-19 infection who are experiencing prolonged fatigue over 6 weeks after their covid-19 rt-pcr negative test. subject has not fully recovered from covid-19 for at least over 6 weeks despite a negative sars-cov-02 test. subjects tested positive for anti-sars-cov-2 antibodies using fda eua approved test. subject is experiencing the following three symptoms for at least over 6 weeks either continually or intermittently with relapses not experienced pre-illness, that interferes with normal daily activities. symptoms must be new symptoms i.e., subject didn't have symptoms, and had not sought medical treatment for the symptoms prior to covid-19: extreme fatigue - feeling overtired with low energy and a strong desire to sleep but unable to have good sleep. body aches - muscle soreness or generalized achiness throughout the body. joint pain - pain in the joints due to inflammation not experienced before illness. chalder fatigue scale bimodal score ≥ 4 at the time of screening. fatigue severity scale (fss) ≥ 4 at the time of screening. fatigue assessment scale score (fas) ≥ 10.5 at the time of screening. beck depression inventory (bdi) score <9 at the time of screening (score of 9 is an exclusion). investigator(s) has access to medical documentation of previous covid-19 treatments. ability of subject to understand and the willingness to sign a written informed consent document. subjects must be reasonably able to return for multiple follow-up visits. adequate venous access. for subjects of child-bearing potential only, willingness to use fda-recommended birth control until 6 months post-treatment. the fda-approved and cleared methods for birth control are listed below: permanent sterilization long-acting reversible contraceptives (larc) contraceptive injection short-acting hormonal methods barrier methods emergency contraception any male subject must agree to use contraceptives and not donate sperm during the study.